生物医药行业：活性胶原贴敷料研究报告

1 2 .................................................................................................. 3 1.1. .................................................................................................. 3 1.1.1. ....................................................................................... 3 1.1.2. ....................................................................................... 4 1.2. .............................................................................................. 8 1.2.1. ............................................................................ 8 1.2.2. ................................................................................... 9 ............................................................................................ 13 2.1. ..................................................................................... 13 2.1.1. .................................................................. 13 2.1.2. .................................................................. 14 2.1.3. ............................................................... 15 2.1.4. ............................................................... 16 ........................................................................................ 18 3.1. .................................................................. 18 3.1.1. ........................................................... 18 3.1.2. ........................................................... 21 3.2. ................................................................................. 22 3.2.1. .......................................................................... 22 3.3. ......................................... 26 3 1.1. 1.1.1. Collagen30% α αIIIIIIIIIIII 4 1.1.2. 28 α I COL1A1 [α1(I)]2α2(I) 67 nm COL1A2 [α1(I)]3 II COL2A1 [α1(II)]3 III COL3A1 [α1(III)]3 5 α V COL5A1 [α1(V)]2α2(V) 9 nm COL5A2 [α1(V)α2(V)α3(V)] COL5A3 [α1(V)]3 XI COL11A1 [α1(XI)α2(XI)α3(XI)] V COL11A2 XXIV COL24A1 [α1(XXIV)]3 XXVII COL27A1 [α1(XXVII)]3 FACIT IX COL9A1 [a1(IX)a2(IX) a3(IX)] II COL9A2 COL9A3 XII COL12A1 [a1(XII)]3 I XIV COL14A1 [a1(XIV)]3 I II XVI COL16A1 a1(XVI) -1 D II 6 α FACIT XIX COL19A1 a1(XIX) N- [a1(XIX)]2 [a1(XIX)]3 [a1(XIX)]4 [a1(XIX)]5 [a1(XIX)]6 XX COL20A1 a1(XX) XXII COL22A1 a1(XXII) - IV COL4A1 [a1(IV)]2a2(IV) COL4A2 [a1(IV)]2a3(IV) COL4A3 [a1(IV)]2a4(IV) COL4A4 [a1(IV)]2a5(IV) COL4A5 [a1(IV)]2a6(IV) VII COL7A1 [a1(VII)]3 XVIII COL18A1 a1(XVIII) 7 α MACITs XIII COL13A1 a1(XIII) XXIII COL23A1 a1(XXIII) XXV COL25A1 a1(XXV) R XXVI COL26A1 a1(XXVI) XVIII COL18A1 a1(XVIII) XV COL15A1 a1(XV) XXVIII COL28A1 a1(XXVIII) 8 1.2. 1.2.1. Collagen-related PeptideCRP • • • • • • • • • • • • 9 • • • • • • • • 1.2.2. 10 1981FDA Zyderm Ⅰ I 2009 1 2 11 Ca(OH)2NaOH 1.2.3. 1 , 2 12